Canaccord Genuity analyst Richard Close reiterated a Buy rating on Livongo Health (LVGO) yesterday and set a price target of $46.00. The company’s shares closed last Tuesday at $33.16.
According to TipRanks.com, Close is a 5-star analyst with an average return of 9.1% and a 57.0% success rate. Close covers the Technology sector, focusing on stocks such as Castlight Health, Health Catalyst, and HealthStream.
Currently, the analyst consensus on Livongo Health is a Strong Buy with an average price target of $39.83, which is a 22.6% upside from current levels. In a report issued on March 27, Morgan Stanley also maintained a Buy rating on the stock with a $36.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $45.69 and a one-year low of $15.12. Currently, Livongo Health has an average volume of 1.87M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Livongo Health, Inc. develops and operates a consumer digital health platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications across multiple chronic conditions. It focuses on diabetes, hypertension, weight management, diabetes prevention, and behavioral health. The company was founded by Kimon Angelides and Glen E. Tullman on October 16, 2008 and is headquartered in Mountain View, CA.
Read More on LVGO:
